Professor, Medicine, University of Washington School of Medicine
Oncology
Dr. Martin A. Cheever, MD
|
|
Give Review
Martin Cheever works in the field of Oncology. He graduated from University of Michigan Medical School. Martin A. Cheever, MD is also published. He has 93 publications published. The lastest publication: "Lung injury induced by alloreactive Th1 cells is characterized by host-derived mononuclear cell inflammation and activation of alveolar macrophages.'
Publications
- PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine.
- The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.
- Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer.
- Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.
- Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an I...
- HER2 dendritic cell vaccines.
- Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor ...
- Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.
- Designing HER2 vaccines.
- Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
- Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.
- Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
- Induction of increased graft-versus-host disease by mouse spleen cells sensitized in vitro to allogeneic tumor.
- High-dose combination chemotherapy for acute nonlymphoblastic leukemia in adults.
- Specific adoptive immunotherapy.
- Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine l...
- Intensification therapy for acute nonlymphoblastic leukemia in adults.
- CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein.
- Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison.
- Combination chemotherapy for acute nonlymphoblastic leukemia in adults.
- Detection of early and delayed antitumor effects following curative adoptive chemoimmunotherapy of established leukemia.
- [Probability of vaccine therapy for pancreas cancer].
- Therapy of leukemia by nonimmune syngeneic spleen cells.
- Donor T cells can be induced to grow and survive long term in vivo without previous host immunosuppression.
- Tumor neutralization, immunotherapy, and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: II. Comparison of cells cultured with and ...
- Specificity of adoptive chemoimmunotherapy of established syngeneic tumors.
- Tumor neutralization, immunotherapy, and chemoimmmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro.
- Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo.
- H-2 restriction of adoptive immunotherapy of advanced tumors.
- Potential uses of interleukin 2 in cancer therapy.
- Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide.
- Requirements for the generation of a Lyt-2+ T-cell proliferative response to a syngeneic tumor in the absence of L3T4+ T-cells.
- Identical twin bone marrow transplantation for hairy cell leukemia.
- Therapy of disseminated tumors by adoptive transfer of specifically immune T cells.
- Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors.
- WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies.
- T-cells for tumor therapy can be obtained from antigen-loaded sponge implants.
- Adoptive immunotherapy of metastatic B16 melanoma with allogeneic immune cells sensitized to minor histocompatibility antigens.
- Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.
- Treatment of established tumor by adoptive immunotherapy with specifically immune T cells.
- Suppression of the in vitro secondary response to syngeneic tumor and of in vivo tumor therapy with immune cells by culture-induced suppressor cells.
- Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate cancer therapy.
- Distinct phenotypic expression of immunogenicity and immunosensitivity in sublines of a tumor.
- Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells.
- Lung injury induced by alloreactive Th1 cells is characterized by host-derived mononuclear cell inflammation and activation of alveolar macrophages.
- Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
- Helper-independent CD8+ cytotoxic T lymphocytes express IL-1 receptors and require IL-1 for secretion of IL-2.
- T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in v...
- Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells.
- Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory.
- T-cell immunity to the joining region of p210BCR-ABL protein.
- T cells specific for a polymorphic segment of CD45 induce graft-versus-host disease with predominant pulmonary vasculitis.
- CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells.
- Therapy with cultured T cells: principles revisited.
- Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis.
- In vitro priming to tumor-associated proteins.
- Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood.
- Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth.
- T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes.
- Effector mechanisms by which adoptively transferred T cells promote tumor eradication.
- IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
- Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with I...
- Antigen-specific cultured T cells can mediate tumor therapy and provide long-term immunologic memory in vivo.
- Il-4 is an endogenous T cell growth factor during the immune response to a syngeneic retrovirus-induced tumor.
- Requirements for T cell recognition and elimination of retrovirally-transformed cells.
- Adoptively transferred antigen-specific T cells can be grown and maintained in large numbers in vivo for extended periods of time by intermittent restimulation with sp...
- Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment.
- Induction of T cells specific for the mutated segment of oncogenic P21ras protein by immunization in vivo with the oncogenic protein.
- CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients.
- Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8.
- Dendritic cells lose ability to present protein antigen after stimulating antigen-specific T cell responses, despite upregulation of MHC class II expression.
- Immunity to the HER-2/neu oncogenic protein.
- Immunity to oncogenic proteins.
- Oncogenic proteins as tumor antigens.
- In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.
- Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.
- T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.
- Retroviral transduction of protein kinase C-gamma into tumor-specific T cells allows antigen-independent long-term growth in IL-2 with retention of functional specific...
- Immunity to WT1 in the animal model and in patients with acute myeloid leukemia.
- HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer.
- Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.
- WT1-specific serum antibodies in patients with leukemia.
- HER-2/neu oncogenic protein: issues in vaccine development.
- Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for ''self'' tumour antigens.
- High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.
- Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
- Development of a CTL vaccine for Her-2/neu using peptide-microspheres and adjuvants.
- Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor.
- Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera.
- Cancer vaccines and immunotherapies: emerging perspectives.
- Translational Research Working Group developmental pathway for immune response modifiers.
- Twelve immunotherapy drugs that could cure cancers.
Schools
University of Mi Med Sch
University Wash Med School
Doctors Specialties
- Internal Medicine
- Oncology
Accepted Insurances
Education
-
University of Washington -
University of Michigan Medical School
Helpful Reviews
Similar Doctors
|
|
Dr. William C. Stewart II, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mayan Bomsztyk, MD |
|
|
Dr. Andrew F. Prouse, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ann M. Alvarez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elihu H. Estey, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Vijayakrishna K. Gadi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William H. Schubach, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Derek L. Stirewalt, MD
This Doctor is OpenDoctor Recommended.
|